Skip to content
Home▶Archive▶Vol. 7 No. 2 (2024)▶Moskowitz syndrome manifesting as recurrent large vessel…
Academia Journal of Medicine
Print ISSN 2663-8282 · Online ISSN 2663-8290
Case Report

Moskowitz syndrome manifesting as recurrent large vessel strokes in  a young male-An original research paper 

Ishana Gaur — Resident Doctor, Department of General Medicine, Civil Hospital, Ahmedabad
Published 30 Jul 2024 Vol. 7 No. 2 (2024), pp. 27-29 ● Open access
Formats:PDF ● Open access
Download PDF

Abstract

Background: Thrombotic thrombocytopenic purpura (TTP) is a rare and  life-threatening condition characterized by microthrombus formation due to a  deficiency of ADAMTS13, which cleaves von Willebrand factor multimers. This  deficiency leads to widespread microangiopathic hemolytic anemia and multiple  organ involvement, particularly affecting the brain, heart, and kidneys. TTP can  present atypically and poses a diagnostic challenge, especially in young patients  with neurological symptoms and thrombocytopenia. Early diagnosis and prompt  initiation of plasma exchange therapy (PEX) and steroids are critical to reduce  mortality. 

KeywordsTTP - Thrombotic Thrombocytopenic PurpuravWF - von Willebrand FactorPEX- Plasma Exchange TherapyADAMTS13 - A Disintegrin and Metalloprotease with Thrombospondin type 1 motif member 13 HUS - Hemolytic Uremic SyndromePLASMIC- Platelet count, hemolysisabsent kidney injury absence of active cancer presence of mycoplasmaand no other cause of thrombocytopenia score ISTH - International Society on Thrombosis and Haemostasis

The full text of this article is available as a PDF.

Download PDF
  1. Török, T. J., Holman, R. C., & Chorba, T. L. (1995). Increasing mortality from thrombotic thrombocytopenic purpura in the United States—Analysis of national mortality data, 1968–1991. American Journal of Hematology, 50(2), 84–90. https://doi.org/10.1002/ajh.2830500205
  2. Terrell, D. R., Williams, L. A., Vesely, S. K., & George, J. N. (2005). The incidence of thrombotic thrombocytopenic purpu ra-hemolytic uremic syndrome: All patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. Journal of Thrombosis and Haemostasis, 3(7), 1432–1436. https://doi.org/10.1111/j.1538-7836.2005.01445.x
  3. Tsai, H.-M. (2010). Pathophysiology of thrombotic thrombo cytopenic purpura. International Journal of Hematology, 91(1), 1–19. https://doi.org/10.1007/s12185-009-0456-1
  4. Amorosi, E. L., & Ultmann, J. E. (1966). Thrombotic thrombo cytopenic purpura. Medicine, 45(2), 139–160. https://doi. org/10.1097/00005792-196603000-00002
  5. George, J. N. (2010). How I treat patients with thrombotic throm bocytopenic purpura: 2010. Blood, 116(20), 4060–4069. https://doi.org/10.1182/blood-2010-07-271445
  6. Sarode, R. (2009). Atypical presentations of thrombotic throm bocytopenic purpura: A review. Journal of Clinical Apheresis, 24(1), 47–52. https://doi.org/10.1002/jca.20129
  7. Downes, K. A., Yomtovian, R., Tsai, H.-M., Silver, B., & Shulman, K. (2004). Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident. Journal of Clinical Apheresis, 19(2), 86–89. https://doi.org/10.1002/
  8. jca.20013
  9. Tsai, H.-M., & Shulman, K. (2003). Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocyto penic purpura. European Journal of Haematology, 70(3), 183–185. https://doi.org/10.1034/j.1600-0609.2003.00055.x

Looking up citing articles…

    Copyright © 2024 Academia Journal of Medicine